Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205736 | 1.00 | PDE2A (0.56) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL18567951 | 0.83 | LMNA (0.44) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL673182 | 0.82 | LMNA (0.45) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL1911427 | 0.82 | LMNA (0.56) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL29519227 | 0.82 | LMNA (0.45) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL2698362 | 0.81 | PDE2A (0.55) | PDE2ALMNATP53HTTNPSR1 | |
| SCHEMBL2502857 | 0.81 | PDE2A (0.55) | PDE2ALMNATP53HTTNPSR1 | |
| SCHEMBL9910111 | 0.81 | PDE2A (0.55) | PDE2ALMNATP53HTTNPSR1 | |
| SCHEMBL16067492 | 0.80 | LMNA (0.41) | PDE2ALMNATRPA1CHRM1SLC6A2 | |
| SCHEMBL13866426 | 0.80 | TP53 (0.63) | PDE2ALMNATP53HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285581-B1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3331863-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| WO-2017021879-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | PDE2A 1/4885LMNA 4660/4885TRPA1 3713/4885 |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | PDE2A 1/4885LMNA 4660/4885TRPA1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.